TCR-NK: A Novel Paradigm to Drive Durable Responses in Solid Cancers
Time: 3:15 pm
day: Day 1 - Track A - Mid
Details:
- TCR based therapies have shown compelling tumour responses across various solid cancers; however, virtually all patients with advanced solid tumours showing initial response to treatment relapse
- Heterogeneity of target expression and / or loss of target have been clinically demonstrated to drive relapse in patients where cancers evade T cell recognition
- Arming NK cells with TCRs serves to provide an “off the shelf” therapeutic that can detect solid cancers with multiple mechanisms (TCR and NK receptors) offering the potential to combat tumour diversity that is limiting the treatment outcome of current therapies
